APA
Goll G. L., Jørgensen K. K., Sexton J., Olsen I. C., Bolstad N., Haavardsholm E. A., Lundin K. E. A., Tveit K. S., Lorentzen M., Berset I. P., Fevang B. T. S., Kalstad S., Ryggen K., Warren D. J., Klaasen R. A., Asak Ø., Baigh S., Blomgren I. M., Brenna Ø., Bruun T. J., Dvergsnes K., Frigstad S. O., Hansen I. M., Hatten I. S. H., Huppertz-Hauss G., Henriksen M., Hoie S. S., Krogh J., Midtgard I. P., Mielnik P., Moum B., Noraberg G., Poyan A., Prestegård U., Rashid H. U., Strand E. K., Skjetne K., Seeberg K. A., Torp R., Ystrøm C. M., Vold C., Zettel C. C., Waksvik K., Gulbrandsen B., Hagfors J., Mørk C., Jahnsen J. & Kvien T. K. (20200507). Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. : Journal of internal medicine.
Chicago
Goll G L, Jørgensen K K, Sexton J, Olsen I C, Bolstad N, Haavardsholm E A, Lundin K E A, Tveit K S, Lorentzen M, Berset I P, Fevang B T S, Kalstad S, Ryggen K, Warren D J, Klaasen R A, Asak Ø, Baigh S, Blomgren I M, Brenna Ø, Bruun T J, Dvergsnes K, Frigstad S O, Hansen I M, Hatten I S H, Huppertz-Hauss G, Henriksen M, Hoie S S, Krogh J, Midtgard I P, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid H U, Strand E K, Skjetne K, Seeberg K A, Torp R, Ystrøm C M, Vold C, Zettel C C, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J and Kvien T K. 20200507. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. : Journal of internal medicine.
Harvard
Goll G. L., Jørgensen K. K., Sexton J., Olsen I. C., Bolstad N., Haavardsholm E. A., Lundin K. E. A., Tveit K. S., Lorentzen M., Berset I. P., Fevang B. T. S., Kalstad S., Ryggen K., Warren D. J., Klaasen R. A., Asak Ø., Baigh S., Blomgren I. M., Brenna Ø., Bruun T. J., Dvergsnes K., Frigstad S. O., Hansen I. M., Hatten I. S. H., Huppertz-Hauss G., Henriksen M., Hoie S. S., Krogh J., Midtgard I. P., Mielnik P., Moum B., Noraberg G., Poyan A., Prestegård U., Rashid H. U., Strand E. K., Skjetne K., Seeberg K. A., Torp R., Ystrøm C. M., Vold C., Zettel C. C., Waksvik K., Gulbrandsen B., Hagfors J., Mørk C., Jahnsen J. and Kvien T. K. (20200507). Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. : Journal of internal medicine.
MLA
Goll G L, Jørgensen K K, Sexton J, Olsen I C, Bolstad N, Haavardsholm E A, Lundin K E A, Tveit K S, Lorentzen M, Berset I P, Fevang B T S, Kalstad S, Ryggen K, Warren D J, Klaasen R A, Asak Ø, Baigh S, Blomgren I M, Brenna Ø, Bruun T J, Dvergsnes K, Frigstad S O, Hansen I M, Hatten I S H, Huppertz-Hauss G, Henriksen M, Hoie S S, Krogh J, Midtgard I P, Mielnik P, Moum B, Noraberg G, Poyan A, Prestegård U, Rashid H U, Strand E K, Skjetne K, Seeberg K A, Torp R, Ystrøm C M, Vold C, Zettel C C, Waksvik K, Gulbrandsen B, Hagfors J, Mørk C, Jahnsen J and Kvien T K. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. : Journal of internal medicine. 20200507.